Trial reportMolecular metabolism2026
Autocrine signaling may regulate exercise-induced interleukin-6 release from human skeletal muscle.
Trial report in Molecular metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06334653 (Exercise-regulated Organ Crosstalk, Influence of IL-6), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exercise-regulated Organ Crosstalk, Influence of IL-6
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContracting skeletal muscle releases interleukin-6 (IL-6) which is primarily cleared by the liver. The tissue-specific regulation of IL-6 and soluble IL-6 receptor (sIL-6R) kinetics remains, however, poorly understood. To characterize tissue-specific IL-6 and sIL-6R exchange during exercise, we combined simultaneous arteriovenous measurements across the contracting leg, splanchnic region, and the brain with, or without, pharmacological IL-6 receptor (IL-6R) blockade.
methodsThirty young, well-trained men were randomized in a double-blind, placebo-controlled design to receive either tocilizumab (IL-6R blockade) or placebo before performing moderate-intensity cycling exercise. Net tissue flux of IL-6 and sIL-6R was determined from arteriovenous concentration differences across the femoral, hepatic, and internal jugular circulation.
resultsDuring exercise, leg IL-6 release increased with both placebo and IL-6R blockade but was significantly augmented by IL-6R blockade, suggesting a potential role for autocrine regulation of local IL-6 release. Under control conditions, the splanchnic bed was the predominant site of IL-6 clearance; however, IL-6R blockade shifted splanchnic IL-6 net balance from uptake to release. In addition, the exercising leg was identified as the source of circulating sIL-6R during exercise, whereas no consistent sIL-6R exchange occurred across the splanchnic bed or brain.
conclusionsThese findings suggest a potential role for IL-6 signaling in the autocrine regulation of IL-6 release from the contracting leg during exercise. Furthermore, exercise increases leg-derived sIL-6R, thereby contributing to increased circulating sIL-6R concentrations, while receptor-mediated splanchnic clearance appears to be a major determinant of systemic IL-6 availability during exercise in humans. CLINICAL TRIAL REGISTRATION NUMBER: Clinicaltrials.gov (NCT06334653).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.